AgomAb Therapeutics NV (NasdaqGS: AGMB)
Health Care · Pharmaceuticals · BE
$9.08
-1.52% today · -38.0% 1Y
AgomAb Therapeutics NV (NasdaqGS: AGMB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $447.17M and employs 62 people.
Over the last twelve months the share price has lost 38.0%, trading between 7.97 and 17.82.
Tweenvest scores AgomAb Therapeutics NV across four factors: quality 50/100, value 71/100. Its strongest factor is value.
AGMB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $447.17M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.95
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $17.82
- 52-week low
- $7.97
- Avg volume (3M)
- —
- Shares outstanding
- 49.25M
- Employees
- 62
- Next earnings
- —
About AgomAb Therapeutics NV
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
- ISIN
- US00860C1027
- Founded
- 2017
- Listed since
- Feb 6, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| iX Biopharma Ltd.Catalist: 42C | $452.33M | S$0.53 | -5.36% |
| DHG Pharmaceutical Joint Stock CompanyHOSE: DHG | $450.55M | ₫89,200.00 | -0.22% |
| Jiangxi Synergy Pharmaceutical Co., Ltd.SZSE: 300636 | $448.91M | CN¥7.16 | +0.99% |
| JW Pharmaceutical CorporationKOSE: A001060 | $447.47M | ₩26,350.00 | -1.50% |
| Shaanxi Panlong Pharmaceutical Group Co., Ltd.SZSE: 002864 | $435.73M | CN¥21.35 | +1.43% |
| Nika Pharmaceuticals, Inc.OTCPK: NIKA | $431.19M | $— | — |
| Guizhou Yibai Pharmaceutical Co., Ltd.SHSE: 600594 | $430.95M | CN¥3.68 | +1.10% |
| SMS Pharmaceuticals LimitedNSEI: SMSPHARMA | $430.28M | Rs444.65 | -5.65% |
Figures last refreshed Oct 11, 2026.